Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression.

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Alzheimer's Disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia.
• Current AD treatments offer only temporary symptomatic relief and do not halt disease progression.
• Novel therapeutic strategies targeting underlying disease mechanisms are urgently needed.

Purpose of the Study:

• To identify novel signaling pathways and therapeutic targets regulating low-density lipoprotein receptor (LDLR) expression in glial cells.
• To explore the potential of LDLR modulation as a therapeutic strategy for Alzheimer's Disease.

Main Methods:

• Conducted a large-scale phenotypic screen of approximately 29,000 compounds.
• Utilized genetic, chemical biology, and pathway analysis to validate identified targets.
• Focused on regulating LDLR expression in glial cells, which are involved in cholesterol metabolism and AD pathogenesis.

Main Results:

• Identified polo like kinase 1 (PLK1), activin receptor like kinase 5 (ALK5), and serotonin transporter (SERT) as novel targets regulating LDLR expression.
• Demonstrated that LDLR modulation can influence amyloid-β clearance and deposition.
• Confirmed the identified targets through subsequent genetic and chemical biology experiments.

Conclusions:

• Phenotypic screening is a viable strategy for discovering novel therapeutic targets in complex neurodegenerative diseases like AD.
• PLK1, ALK5, and SERT represent promising targets for developing new Alzheimer's treatments by modulating LDLR expression.
• This research opens new avenues for therapeutic intervention in Alzheimer's Disease by targeting glial cell signaling pathways.